KRAS and cancer: The ERH expression is inversely correlated with survival of cancer patients whose cancers harbor KRAS mutations [27], while it is not associated with survival in those patients whose cancers are wild-type KRAS or harbor other oncogenic mutations such as EGFR or PI3K mutations.